MSCL fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
MSCL does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company